The implementation of the Affordable Care Act and its resulting market turbulence has not created the operation challenges for payers that was expected, according to a report from athenahealth, Inc.
The implementation of the Affordable Care Act and its resulting market turbulence has not created the operation challenges for payers that was expected, according to a report from athenahealth, Inc.
The PayerView Report measures payers' financial, administrative, and transactional performance, and revealed that payers offering health plans in Medicaid expansion states and on the health insurance exchanges are actually performing better than those not participating.
"As providers increasingly take part in risk-sharing models and navigate big changes such as ICD-10, finding payer partners that have strong core operations and are differentiated on performance and transparency will be key," Todd Rothenhaus, chief medical officer of athenahealth said in a statement. "The financial, administrative, and transaction metrics that we use to rank payers provides a powerful guide for providers as they work to serve patients and get paid most efficiently."
athenahealth found that in 2013 and 2014 Medicaid expansion states performed better than non-expansion states. Blue Cross Blue Shield plans and commercial payers offering health plans in the health exchanges performed better than carriers ot in health exchanges in both years. Payers participating in ACA implementation appear to be performing better overall.
Read more at athenahealth: http://bit.ly/1Asbsda
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
2 Commerce Drive
Cranbury, NJ 08512